J. Jensen

Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma

N. Stambler, L. Kostakoglu, D. Pryma, 2018, The Journal of Nuclear Medicine.

Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).

Steve Y. Cho, P. Carroll, A. Iagaru, 2020 .

Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma

N. Stambler, S. Goldsmith, D. Pryma, 2018, The Journal of clinical endocrinology and metabolism.

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY)

P. Carroll, K. Pienta, M. Morris, 2021, The Journal of urology.

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

Steve Y. Cho, P. Carroll, A. Iagaru, 2021, Clinical Cancer Research.

Abstract PO-077: Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress

J. Czernin, O. Sartor, N. Fleshner, 2021 .

Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).

J. Czernin, N. Fleshner, V. Prasad, 2021 .

Results from the OSPREY trial: A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients with PRostate Cancer - Examination of Diagnostic AccuracY

P. Carroll, K. Pienta, M. Morris, 2019 .